WHAT IS CLAIMED IS:

1. A compound structurally represented by Formula I



(I)

or pharmaceutically acceptable salts thereof wherein:

G^1 is $-CH_2-$, or $-CH_2-CH_2-$,

G^2 is $-CH_2-$, or $-C(O)-$,

or G^1 and G^2 taken together combine to form $-CH=CH-$ or $-CH_2-CH=CH-$,

Y is

$-OCH_2CH_2N$-piperidinyl,

$-OCH_2CH_2CH_2N$-piperidinyl,

$-OCH_2CH_2N$-pyrrolidinyl,

$-OCH_2CH_2CH_2N$- pyrrolidinyl,

X is H, $-COR^3$, $-CH_2R^4$, $-SO_2R^5$,

R^3 is

$-(C_1-C_8)$ alkyl, optionally substituted with 1 to 3 halogens,

$-(C_3-C_8)$ cycloalkyl, optionally substituted with 1 to 3 halogens,

$-O(C_1-C_8)$ alkyl, optionally substituted with 1 to 3 halogens,



, wherein R^6 is -(C_1-C_6) alkyl, or –COO-(C_1-C_6) alkyl,

-Furanyl,

-Thienyl,

-NH-phenyl,

-NH-(C_1-C_4)alkyl-phenyl,

-NH-(C_1-C_8) alkyl, optionally substituted with 1 to 4 halogens,

-NH-(C_3-C_8) cycloalkyl, optionally substituted once or twice with halogens,

-CH_2-Pyridinyl,

-CH_2N (C_1-C_6) alkyl (C_1-C_6) alkyl,

-CH_2N-phenyl,

R^4 is

-(C_1-C_8) alkyl, optionally substituted with 1 to 4 halogens,

-(C_3-C_8) cycloalkyl,

-(C_1-C_8) alkyl-NH_2,

-(C_1-C_4) alkyl –phenyl,

-CH_2N-phenyl,

-phenyl-O-(C_1-C_4) alkyl –phenyl,

-(C_1-C_4) alkyl-O-(C_1-C_4) alkyl-phenyl,

-CH_2NCO_2-(C_1-C_6) alkyl,

-Phenyl,

-Thienyl,

-Furanyl,

-Imidazolyl,

-Naphthyl,



, wherein R^6 is -(C_1-C_6) alkyl, or -COO-(C_1-C_6) alkyl,

-Biphenyl, and

R^5 is

-Phenyl,

-(C_1-C_4) alkyl,

-(C_1-C_4) alkyl –phenyl.

2. The compound of claim 1, wherein G1 is -CH2-.
3. The compound of claim 1, wherein G1 -CH2-CH2-.
4. The compound of claim 2, wherein Y is in the 5 position.
5. The compound of claim 3, wherein Y is in the 6 position.
6. The compound of claim 4, wherein X is -COR^3.
7. The compound of claim 1, selected from the group consisting of:

	Example Number	Structure	
	1		
	2		
	3		

	4		
	5		
	6		
	7		
	8		
	9		

	10		
	11		
	12		
	13		
	14		

	15		
	16		
	17		
	18		
	19		
	20		

	21		
	22		
	23		
	24		
	25		
	26		

	27		
	28		
	29		
	30		
	31		

	32		
	33		
	34		
	35		
	36		

	37		
	38		
	39		
	40		
	41		

	42		
	43		
	44		
	45		

	46		
	47		
	48		
	49		
	50		

	51	 Chiral	
	52	 Chiral	
	53		
	54		
	55		

	56		
	57	Chiral 	
	58		
	59	Chiral 	
	60	Chiral 	

	61		
	62		
	63		
	64		

or a pharmaceutically acceptable salt or solvate thereof.

8. A pharmaceutical composition which comprises a compound of any of claims 1-7 and a pharmaceutically acceptable carrier.

9. A method of selectively increasing histamine levels in cells by contacting the cells with an antagonist of the histamine H3 receptor, said antagonists comprising a compound of any of claims 1-7.

10. The method of Claim 9 wherein the antagonist is a pharmaceutical composition of claim 8.

11. The method of Claim 9 wherein the antagonist is characterized by selectively binding the histamine H3R receptor, relative to the histamine H4R receptor.

12. A method for treatment or prevention of obesity which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of any of Claims 1-7.

13. The method of Claim 12 wherein the antagonist is a pharmaceutical composition of claim 8.

14. A method for treatment or prevention of a disorder or disease in which inhibition of the histamine H3 receptor has a beneficial effect which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of any of claims 1-7.